Clinical Trial Update: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a PD-1 antibody plus mXELIRI versus mXELIRI alone in second-line esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)
• mXELIRI (mXELIRI)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | Phase 3 | Status: UNKNOWN